Plain-English translation of NCT06316856 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CD5 chimeric antigen receptor (CAR) T-cell therapy, a treatment that uses your own or a donor's immune cells that have been engineered in a lab to attack cancer. Researchers are studying whether this medication is safe and whether it can help patients whose T-cell blood cancers have stopped responding to standard treatments. The trial will enroll about 54 patients and test different doses of the treatment to find the best one.
Many patients with T-cell blood cancers run out of treatment options when their cancer stops responding to chemotherapy and other standard therapies. This medication represents a new approach that harnesses the body's own immune system to fight these hard-to-treat cancers, offering hope to patients who have limited options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive a 'lymphodepleting' treatment (chemotherapy that temporarily weakens your immune system to make room for the new cells). Then you will receive an infusion of the engineered immune cells, which may come from your own body, a previous donor, or a newly matched donor. Researchers will monitor you closely for at least 30 days after the infusion to watch for side effects and to see how well the treatment works, with the main assessment happening around 3 months after your infusion.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China